Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Endocrine 1CNS 1

Conditions

Neoplasms 6Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Small Cell Lung Carcinoma 1Neoplasm Metastasis 1Melanoma 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Neuroendocrine 1

Interventions

Magnetic Resonance Spectroscopy 6X-Rays 5Specimen Handling 5Phantoms, Imaging 5Nuclear Medicine Department, Hospital 4Cisplatin 4Biopsy 4selpercatinib 3larotrectinib 3Vincristine 3Carboplatin 3erdafitinib 2ensartinib 2Temozolomide 2Radiotherapy 2Methotrexate 2Cyclophosphamide 2Chemotherapy, Adjuvant 2ulixertinib 1tipifarnib 1tazemetostat 1palbociclib 1olaparib 1niraparib 1neratinib 1lenvatinib 1ivosidenib 1ibrutinib 1entrectinib 1durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Central Nervous System Neoplasms × budigalimab × Clear all
NCT05599984 2026-05-07

Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors

AbbVie

Phase 1 Active not recruiting
288 enrolled
CNSEndocrineThoracic

Neoplasms, Central Nervous System Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡